Locus Fermentation Solutions (Locus FS), a Solon, Ohio-based green tech company that produces natural alternatives to chemicals, has raised $ 117 million in fresh funding. The IP-insurance-backed debt financing arranged by Jefferies brought its total raise to over $250 million.
The value of Locus Fermentation Solutions’ intellectual property (IP) and collection of more than 1,300 biomanufacturing technology patent applications served as the basis for the financing.
Markel, Liberty Specialty Markets, CNA, Aspen, and Fidelis participated in a collateral insurance coverage based on Locus FS’s intellectual property. The insurance was appraised using the sector-leading valuation expertise of global professional services firm Aon.
“The company’s success has led to investments and agreements with various other strategic partners, including Dow and Anew Climate. Support and funding from these partnerships are accelerating commercial adoption of the company’s solutions,” Lefkowitz said.
For clients’ decarbonization goals to be met more quickly and profitably, Locus FS uses patented biomanufacturing technology to supply biological alternatives to chemicals.
These solutions have been specifically designed to solve climate change, food security, product sustainability, water contamination, demand for oil and minerals, and more. The biobased substances are made available for sale through operating divisions dedicated to each industry after being field-tested.
Locus FS is actively working to advance 11 of the 17 Sustainable Development Goals of the United Nations and supports clients in achieving their net-zero commitments across all industries. More than 160 individuals work for the organization, with eleven offices spread throughout five states.
Locus FS produces biological solutions for various industries to lower their carbon footprint
Using proprietary biomanufacturing technology, Locus Fermentation Solutions (Locus FS), founded in 2013 and directed by CEO Andrew Lefkowitz, provides clients with biological alternatives to chemicals that expedite the achievement of decarbonization targets.
“Through scientific breakthroughs backed by intellectual property, strategic funding and corporate partnerships, we’re accelerating the pivotal role customized biologicals can play in advancing the decarbonization and ESG goals for our clients,” said Andrew Lefkowitz, chairman and CEO of Locus FS.
To promote ESG objectives, Locus FS converts biologicals derived from 100 percent sustainable agricultural resources into chemical substitutes with superior performance and cost parameters.
These solutions are designed to tackle issues including climate change, food security, product sustainability, water contamination, and mineral and oil demand that are ESG-related on a global scale.
“The immediate need for solutions that reduce the global carbon footprint has never been more urgent, but production limitations, high costs and inconsistent performance have hindered the implementation of biological alternatives,” added Andrew Lefkowitz.
Locus FS is now a world authority for biobased, non-GMO, palm-free, and low-carbon solutions. The method of biomanufacturing used by the company entails isolating and fermenting unique microorganisms and the biosurfactants they create.
The resulting biologicals are explicitly made for usage in all chemical-dependent sectors. They are intended to further ESG objectives.
